PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-2.49%
Revenue decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate if market share loss is temporary.
-2.63%
Cost reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive advantage potential.
-1.92%
Gross profit decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive position.
0.58%
Margin change of 0.58% versus flat Medical - Pharmaceuticals margins. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.95%
Other expenses change of 10.95% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify efficiency.
-1.23%
Operating expenses reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
-2.40%
Total costs reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
6.06%
Interest expense change of 6.06% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify control.
14.36%
D&A growth exceeding 1.5x Medical - Pharmaceuticals median of 2.10%. Jim Chanos would check for overinvestment.
-0.24%
EBITDA decline while Medical - Pharmaceuticals median is 0.85%. Seth Klarman would investigate causes.
2.31%
Margin change of 2.31% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
-4.40%
Operating income decline while Medical - Pharmaceuticals median is 4.23%. Seth Klarman would investigate causes.
-1.96%
Operating margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
17.46%
Other expenses growth while Medical - Pharmaceuticals reduces costs. Peter Lynch would examine differences.
-2.72%
Pre-tax income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-0.24%
Pre-tax margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-2.25%
Tax expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
-3.10%
Net income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-0.63%
Net margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-3.10%
EPS decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-3.10%
Diluted EPS decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.